logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Cyclerion Therapeutics, Inc.

Calculating rank
USPTO Granted Patents = 25

% Expired Patents = 4.0



Trademarks = 4

Forward Citations = 28

Loading Chart...
Loading Chart...

40 inventors (with patents filed for the assignee):

goldMedal Takashi Nakai (11 out of 23 patents)

silverMedal Song Xue (10 out of 12 patents)

bronzeMedal Rajesh R Iyengar (10 out of 26 patents)

4.  Paul A Renhowe (10 out of 59 patents)

5.  Thomas Wai-Ho Lee (9 out of 17 patents)

6.  Glen Robert Rennie (9 out of 32 patents)

7.  Joon Jung (9 out of 23 patents)

8.  Timothy Claude Barden (9 out of 19 patents)

9.  Vishnu Vardhan Reddy Karnati (8 out of 8 patents)

10.  G-Yoon Jamie Im (7 out of 13 patents)

11.  Ara Mermerian (7 out of 18 patents)

12.  James Edward Sheppeck (6 out of 27 patents)

13.  Robert C Livingston (6 out of 7 patents)

14.  Wayne C Schairer (6 out of 6 patents)

15.  Ahmad Hashash (6 out of 8 patents)


25 patents:

1. 12758550 - Treatment of diabetic nephropathy with an sGC stimulator (2026-10-13),
2. 12275724 - Processes and intermediates for the preparation of soluble guanylate cyclase stimulators (2025-04-14),
3. 12247025 - Processes for preparation of soluble guanylate cyclase stimulators (2025-03-11),
4. 12030874 - Processes and intermediates for the preparation of soluble guanylate cyclase stimulators (2024-07-09),
5. 11834444 - Processes for preparation of soluble guanylate cyclase stimulators (2023-12-05),
6. 11773089 - Process for preparation of soluble guanylate cyclase stimulators (2023-10-03),
7. 11731977 - SGC stimulators (2023-08-22),
8. 11708361 - Processes and intermediates for the preparation of soluble guanylate cyclase stimulators (2023-07-25),
9. 11690828 - Treatment of CNS diseases with sGC stimulators (2023-07-04),
10. 11572358 - Solid forms of an sGC stimulator (2023-02-07),
11. 11466015 - Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators (2022-10-11),
12. 11466014 - Process for preparing soluble guanylate cyclase stimulators (2022-10-11),
13. 11389449 - Treatment of metabolic syndrome with an sGC stimulator (2022-07-19),
14. 11357777 - Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) (2022-06-14),
15. 11319308 - Processes for preparation of soluble guanylate cyclase stimulators (2022-05-03),
Company Overview
Cyclerion Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, focused on developing innovative therapies for neurological diseases. The company specializes in the research and advancement of treatments that target the underlying mechanisms of various central nervous system disorders. By leveraging its expertise in nitric oxide signaling and related pathways, Cyclerion aims to address significant unmet medical needs and improve patient outcomes through its novel drug candidates.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

25 Patents

#112 in Cambridge, MA

#807 in Massachusetts

#13,388 in US

#25,764 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Cyclerion Therapeutics, Inc.

Forward Citations = 28

40 inventors:

goldMedal Takashi Nakai (11 out of 23 patents)

silverMedal Song Xue (10 out of 12 patents)

bronzeMedal Rajesh R Iyengar (10 out of 26 patents)

4.  Paul A Renhowe (10 out of 59 patents)

5.  Thomas Wai-Ho Lee (9 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cyclerion Therapeutics, Inc.. Retrieved from https://idiyas.com/company/cyclerion-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…